The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | The efficacy of bispecific antibodies targeting BCMA or GPRC5D in relapsed myeloma after CAR-T
In this video, Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, briefly comments on the efficacy of bispecific antibodies targeting BCMA or GPRC5D in relapsed multiple myeloma (MM) after CAR T-cell therapy. A multi-center international study found that teclistamab and talquetamab induced encouraging responses and overall survival (OS) in this patient population. Dr Gagelmann also highlights that the timing of relapse did not impact outcomes, making these agents viable treatment options even in early relapse after CAR-T. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We recently published an also multi-center international study looking into patients who relapsed after CAR-T and trying to identify the best or the optimal salvage therapy. So until now it wasn’t really known whether we can do bispecific antibody treatment for anti-BCMA relapse after CAR T-cell therapy for multiple myeloma. And what we showed is that you can safely apply it...
We recently published an also multi-center international study looking into patients who relapsed after CAR-T and trying to identify the best or the optimal salvage therapy. So until now it wasn’t really known whether we can do bispecific antibody treatment for anti-BCMA relapse after CAR T-cell therapy for multiple myeloma. And what we showed is that you can safely apply it. So either teclistamab or talquetamab induced the best responses with excellent overall survival for patients who relapsed. But even and most importantly that the timing of relapse did not matter, irrespective of the bispecific antibodies. So you can give teclistamab or talquetamab even in early relapse after CAR-T.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
